Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: The invention described herein is based in part on the discovery of a protein/peptide crosslink, which introduces fluorescent properties, and which has been applied to synthesize analogues of melanocortin and amanitin as choice peptides to be explored in the context of isoindole peptides. Without limitation, it is expected that those trained in the art of peptide synthesis and stapling would appreciate the consequences of this invention such that other peptides of varied length can be similarly constrained by isoindole staples as featured herein.

Abstract: The present invention relates to gene expression profiles for B-cell lymphoma. More specifically, the present invention relates to gene expression profiles for diagnosis, prognosis or therapy selection for an aggressive B-cell lymphoma.

Abstract: A Raman endoscope for use in obtaining in vivo Raman spectra in the peripheral airways of the lungs and a method of constructing the Raman endoscope are disclosed. The endoscope has a tubular sheath containing a fiber bundle. The sheath has an outer diameter of less than 1.35 mm. The sheath is made of fluorinated ethylene propylene. The sheath is flexible along its length from a first end to a point along the sheath so that it can navigate sharp turns within the peripheral airways. A layer of coating covers the sheath along a terminal length and a probe tip of the fiber bundle. The terminal length extends along a length of the sheath extending from a second end opposite to the first end to the point. Terminal length is rigid to facilitate advancement of the endoscope towards the lesion of interest. Terminal length is 5 mm or less.

Abstract: A system provides combined diffuse optical microscopy (DOM) and fluorescence endomicroscopy (FE). The system may use a single light source which generates structured illumination for both modalities. FE and DOM images may be displayed for qualitative assessment. Quantitative assessments may be based on both FE and DOM images. The quantitative assessments may be applied to characterize tissues. Some embodiments provide multi-spectral DOM.

Abstract: Systems for confocal Raman spectroscopy of points of interest or regions of interest with concurrent imaging are disclosed. The imaging may be used for real time selection of points of interest or regions of interest for Raman spectroscopy and to monitor for unwanted motions of a sample while Raman spectra are acquired. Disclosed embodiments apply Reflectance confocal microscopy (RCM) in a confocal Raman spectroscopy system. A single laser may be used as a light source for both RCM and micro-Raman spectroscopy. A Faraday optical isolator may be applied to extract RCM signals for imaging Systems as described herein have example application for ex vivo sample and in vivo skin measurement.

Abstract: A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be —CO2H, —SO2H, —SO3H, —PO2H, or —PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.

Abstract: Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.

Abstract: A device may obtain first information relating to one or more first lung nodules identified in first imaging of a chest of a patient and second information relating to one or more second lung nodules identified in second imaging of the chest of the patient. The device may provide the first information and the second information to a machine learning model. The device may determine, using the machine learning model, a risk of lung cancer associated with the patient based on an elapsed time between performance of the first imaging and the second imaging and differences between the first information and the second information. The risk of lung cancer may have an inverse correlation to the elapsed time and a direct correlation to the differences.

Abstract: The invention described herein is based in part on the discovery of a protein/peptide crosslink, which introduces fluorescent properties, and which has been applied to synthesize analogues of melanocortin and amanitin as choice peptides to be explored in the context of isoindole peptides. Without limitation, it is expected that those trained in the art of peptide synthesis and stapling would appreciate the consequences of this invention such that other peptides of varied length can be similarly constrained by isoindole staples as featured herein.

Abstract: A compound is provided comprising a melanocortin 1 receptor (MC1R) targeting peptide (MC1RTP), a radiolabeling group, and a linker joining the MC1RTP to the radio labeling group. The MC1RTP is linear or cyclized, and comprises a sequence of Formula I or Formula II: Xaa1-Xaa2a-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7a (I) or Xaa1-Xaa2b-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7b (II). Xaa1 is L-/D-Nle, L-/D-Nle, L-/D-Ala, L-/D-Leu, L-/D-Ile, D-Ile, L-/D-Cys, L-/D-Met, L-/D-Phe, L-/D-Trp, L-/D-Val, L-/D-Nal, L-/D-2-Nal, Gly, L-/D-?-aminobutryic acid, L-/D-norvaline, or L-/D-homonorleucine. Xaa2a and Xaa7b are L-/D-Cys, L-/D-Asp, L-/D-Glu, L-/D-2-Aad, L-/D-3-Aad, L-/D-Pra, L-/D-Hpg, or L-/D-Bpg. Xaa2b and Xaa7a are L-/D-Cys, L-/D-Lys, L-/D-Orn, L-/D-Dab, L-/D-Dap, L-/D-Lys(N3), L-/D-Orn(N3), L-/D-Dab(N3), L-/D-Dap(N3), L-/D-2-(5?-azidopentyl)alanine, or L-/D-2-(6?-azidohexyl)alanine. Xaa3 is L-/D-His, Pro, beta-(1,2,3-triazol-4-yl)-L-alanine, beta-(1,2,3-triazol-4-yl)-D-alanine, 1,2,4-triazole-3-alanine, or 1,2,4-triazole-3-D-alanine.

Abstract: The present disclosure provides a method for diagnosing a head and neck cancer in a subject. The method comprises the steps of: a) measuring an expression level of miR-125b or miR-342 and miR-125b in a sample from the subject; b) measuring an expression level of a normalizing miR in the sample and normalizing the measured expression level of miR-125b or miR-342 and miR-125b using the measured expression level of the normalizing miR; and c) diagnosing a head and neck cancer in a subject having a normalized measured expression level of miR-125b elevated relative to a reference expression level of miR-125b or having a ratio of normalized measured expression level of miR-342 to normalized measured expression level of miR-125b reduced relative to a reference ratio of expression level of miR-342 to expression level of miR-125b. Uses and kits associated with the herein disclosed methods are also disclosed.

Abstract: The present invention provides a method and apparatus to decrease acute and late skin toxicity for breast cancer patients undergoing radiation therapy. This invention will enable better breast positioning during therapy, eliminating skin folds and reducing the skin dose below that required for development of moist desquamation. The present invention has the potential to reduce the volume of normal tissue and organs at risk of being irradiated during a course of whole breast radiation therapy.

Abstract: A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF3)-containing moiety configured for 19F/18F exchange or a precursor thereof; and optionally a cell-targeting domain.

Abstract: There is provided bombesin-derived compounds of Formula Ia (RX-L-Xaa1-Gln-Trp-Ala-Val-Xaa2-His-Xaa3-?-Xaa4-NH2). RX comprises a radionuclide chelator or a trifluoroborate-containing prosthetic group. L is a linker. Xaa1 is D-Phe, Cpa (4-chlorophenylalanine), D-Cpa, Tpi (2,3,4,9-tetrahydro-1H-pyrido[3,4b]indol-3-carboxylic acid), D-Tpi, Nal (naphthylalanine), or D-Nal. Xaa2 is Gly, N-methyl-Gly or D-Ala. Xaa3 is Leu, Pro, D-Pro, or Phe. Xaa4 is Pro, Phe, Tac (thiazolidine-4-carboxylic acid), Nle (norleucine), 4-oxa-L-Pro (oxazolidine-4-carboxylic acid). The symbol ? represents a reduced peptide bond between Xaa3 and Xaa4 in which ? is CH2—N when Xaa4 is Pro, Tac or 4-oxa-L-Pro, or ? is CH2N(R) when Xaa4 is Phe or Nle wherein R is H or C1-C5 linear or branched alkyl. There is also provided the use of such compounds as imaging agents or therapeutic agents.

Abstract: Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: Disclosed is a respiratory treatment apparatus that may be especially helpful for pediatric patients, though it may be useful for patients of all ages. In one embodiment, the apparatus comprises an endotracheal tube that is physically coupled to a bronchial blocker in a non-concentric fashion. In another embodiment, the apparatus comprises an endotracheal tube that is physically coupled to a steering balloon apparatus. The endotracheal tube, bronchial blocker, and/or steering balloon apparatus may be non-unitary components that are attachable to one another with one or more attachment structures, and once physically coupled, may be put to use. The endotracheal tube and bronchial blocker and steering balloon apparatus may be selected from a plurality of endotracheal tubes and bronchial blockers and steering balloon apparatus, to create an assembled apparatus that meets the needs of the patient.

Abstract: The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

Abstract: A compound is provided comprising a melanocortin 1 receptor (MC1R) targeting peptide (MC1RTP), a radiolabeling group, and a linker joining the MC1RTP to the radiolabeling group. The MC1RTP is linear or cyclized, and comprises a sequence of Formula I or Formula II: Xaa1-Xaa2a-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7a (I) or Xaa1-Xaa2b-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7b (II). Xaa1 is L-/D-Nle, L-/D-Nle, L-/D-Ala, L-/D-Leu, L-/D-Ile, D-Ile, L-/D-Cys, L-/D-Met, L-/D-Phe, L-/D-Trp, L-/D-Val, L-/D-Nal, L-/D-2-Nal, Gly, L-/D-?-aminobutryic acid, L-/D-norvaline, or L-/D-homonorleucine. Xaa2a and Xaa7b are L-/D-Cys, L-/D-Asp, L-/D-Glu, L-/D-2-Aad, L-/D-3-Aad, L-/D-Pra, L-/D-Hpg, or L-/D-Bpg. Xaa2b and Xaa7a are L-/D-Cys, L-/D-Lys, L-/D-Orn, L-/D-Dab, L-/D-Dap, L-/D-Lys(N3), L-/D-Orn(N3), L-/D-Dab(N3), L-/D-Dap(N3), L-/D-2-(5?-azidopentyl)alanine, or L-/D-2-(6?-azidohexyl)alanine. Xaa3 is L-/D-His, Pro, beta-(1,2,3-triazol-4-yl)-L-alanine, beta-(1,2,3-triazol-4-yl)-D-alanine, 1,2,4-triazole-3-alanine, or 1,2,4-triazole-3-D-N alanine.

Abstract: This application relates to compounds of Formula (I-a) or Formula (I-b), or is salts or solvates thereof. R1 is —(CH2)5CH3 or comprises 2-4 fused benzene rings. R2 is I, Br, F, Cl, H, OH, OCH3, NH2, NO2 or CH3. R3 is a peptide-bonded glycine, aspartate or glutamate or is glutamate peptide bonded through Cdelta. L is —CH2NH—, —(CH2)2NH—, —(CH2)3NH—, or —(CH2)4NH—. R4 is a radiometal chelator optionally bound by a radiometal. Variable ‘n’ is 1-3. The compounds may be useful for imaging prostate specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer).